Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".

PloS one - 1 Jan 2021

Mühlbacher Axel C, Sadler Andrew

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Genotype
Share to Germany
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 33600462
DOI: 10.1371/journal.pone.0245480
PMCID: PMC7891755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".PMID 33600462Read ↗

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.Semantic proximity Read ↗

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.Semantic proximity Read ↗

Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.Semantic proximity Read ↗

What is the role of sofosbuvir in treating hepatitis C infection?Semantic proximity Read ↗

Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.Semantic proximity Read ↗

Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.Semantic proximity Read ↗

Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702.Semantic proximity Read ↗

[Cost-effectiveness of chronic hepatitis C treatment in Spain].Semantic proximity Read ↗

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.Semantic proximity Read ↗

Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.Semantic proximity Read ↗

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.Semantic proximity Read ↗

[Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.